Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.53 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.53 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13919692 | 0.89 | CARM1 (0.62) | CARM1PRMT6PRMT1PRMT8SIGMAR1 | |
| SCHEMBL28984365 | 0.84 | SMN1; SMN2 (0.48) | CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL12514044 | 0.84 | SMN1; SMN2 (0.40) | CARM1PRMT6PRMT1PRMT8HRH3 | |
| SCHEMBL18782391 | 0.84 | SMN1; SMN2 (0.37) | CARM1PRMT6PRMT1PRMT8TDP1 | |
| SCHEMBL18286784 | 0.82 | SMN1; SMN2 (0.43) | CARM1PRMT6PRMT8L3MBTL1HRH3 | |
| SCHEMBL8258583 | 0.82 | CARM1 (0.48) | CARM1PRMT6PRMT8L3MBTL1HRH3 | |
| SCHEMBL18782450 | 0.81 | KDM4E (0.44) | HRH3KDM4E | |
| SCHEMBL23594338 | 0.81 | SMN1; SMN2 (0.45) | CARM1PRMT6PRMT1PRMT8SIGMAR1 | |
| SCHEMBL18568453 | 0.80 | HRH3 (0.52) | CARM1PRMT6PRMT8L3MBTL1HRH3 | |
| SCHEMBL12309176 | 0.80 | HRH3 (0.52) | CARM1PRMT6PRMT8L3MBTL1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202367-B2 | Heterocyclic compounds and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170114053-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160355527-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN INC (US) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202367-B2 | Heterocyclic compounds and methods of use thereof | HAVCR2, AR, AKR7A2 | CARM1 632/4885PRMT6 1514/4885PRMT1 895/4885 |
| US-20170114053-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | HAVCR2, AR, AKR7A2 | CARM1 632/4885PRMT6 1514/4885PRMT1 895/4885 |
| US-20160355527-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ABL1, ERBB2, LCK | CARM1 1727/4885PRMT6 606/4885PRMT1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.